Search
Acrylic Acid
go.drugbank.com/drugs/DB02579InvestigationalA α,β-unsaturated monocarboxylic acid that is ethene substituted by a carboxy group.
Categories: Compounds used in a research, industrial, or household settingBufogenin
go.drugbank.com/drugs/DB19835ExperimentalBufogenin is a small molecule drug. Bufogenin has a monoisotopic molecular weight of 384.23 Da.
Categories: Compounds used in a research, industrial, or household settingCintredekin besudotox
go.drugbank.com/drugs/DB05305InvestigationalThe IL13 portion binds to receptors on the tumor.
ISIS 113715
go.drugbank.com/drugs/DB05506InvestigationalIn early trials, ISIS 113715 induced statistically significant improvements in multiple measures of glucose control along with statistically significant reductions in LDL-cholesterol.
INGN 225
go.drugbank.com/drugs/DB05325InvestigationalINGN 225 is currently in Phase 1/2 trials in patients with small cell lung cancer and breast cancer. … INGN 225 is a therapeutic consisting of a cancer patient's own immune cells treated with an adenovector carrying the human p53 gene, Ad-p53.
Categories: Complex MixturesCefadroxil
go.drugbank.com/drugs/DB01140ApprovedInvestigationalVet approvedWithdrawnLong-acting, broad-spectrum, water-soluble, cephalexin derivative.
Dolasetron
go.drugbank.com/drugs/DB00757ApprovedInvestigationalDolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative
Rocaglamide
go.drugbank.com/drugs/DB15495Experimental[didesmethylrocaglamide]) are currently being studied for use as chemotherapeutic agents in the treatment of various leukemias, lymphomas, and carcinomas, as well as adjuvant therapy in the treatment of … [A186796] Reports of _Aglaia_ anti-tumor activity date back as far as 1973, and rocaglamide-A was first isolated in 1982 from the species _A. elliptifolia_.
AT-301
go.drugbank.com/drugs/DB16507InvestigationalAT-301 was under investigation in clinical trial NCT01675284 to evaluate the safety, reactogenicity, and humoral immune responses to an inactivated H5N1 influenza vaccine